company background image
RHT

Resonance HealthASX:RHT Stock Report

Market Cap

AU$53.0m

7D

39.5%

1Y

-25.0%

Updated

18 Oct, 2021

Data

Company Financials
RHT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

RHT Overview

Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services in the Asia Pacific, North America, Europe, the Middle East, and Africa.

Price History & Performance

Summary of all time highs, changes and price drops for Resonance Health
Historical stock prices
Current Share PriceAU$0.12
52 Week HighAU$0.08
52 Week LowAU$0.33
Beta0.53
1 Month Change20.00%
3 Month Change-27.27%
1 Year Change-25.00%
3 Year Change313.79%
5 Year Change328.57%
Change since IPO-99.26%

Recent News & Updates

Shareholder Returns

RHTAU Medical EquipmentAU Market
7D39.5%-0.7%0.9%
1Y-25.0%-4.9%20.2%

Return vs Industry: RHT underperformed the Australian Medical Equipment industry which returned -4.9% over the past year.

Return vs Market: RHT underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is RHT's price volatile compared to industry and market?
RHT volatility
RHT Beta0.53
Industry Beta0.57
Market Beta1

Stable Share Price: RHT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: RHT's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aMitchell Wellshttps://www.resonancehealth.com

Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services in the Asia Pacific, North America, Europe, the Middle East, and Africa. Its principal product is FerriScan, a non-invasive liver diagnostic technology used for the measurement of liver iron concentration (LIC). The company also provides FerriSmart, an artificial intelligence (AI) driven system for the automated real-time measurement of LIC; HepaFat-AI, an AI driven system for the automated real-time multi-metric measurement of liver fat; Cardiac T2, a dual analysis service with FerriScan to provide information regarding body iron stores; HepaFat-Scan, a non-invasive MRI-based solution for the measurement of volume fraction of fat in liver tissue; and Bone Marrow R2-MRI for the assessment of iron levels in the bone marrow.

Resonance Health Fundamentals Summary

How do Resonance Health's earnings and revenue compare to its market cap?
RHT fundamental statistics
Market CapAU$53.03m
Earnings (TTM)AU$585.86k
Revenue (TTM)AU$3.78m

94.5x

P/E Ratio

14.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RHT income statement (TTM)
RevenueAU$3.78m
Cost of RevenueAU$0
Gross ProfitAU$3.78m
ExpensesAU$3.19m
EarningsAU$585.86k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.0013
Gross Margin100.00%
Net Profit Margin15.50%
Debt/Equity Ratio0%

How did RHT perform over the long term?

See historical performance and comparison

Valuation

Is Resonance Health undervalued compared to its fair value and its price relative to the market?

94.49x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: RHT (A$0.12) is trading above our estimate of fair value (A$0.03)

Significantly Below Fair Value: RHT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RHT is poor value based on its PE Ratio (94.5x) compared to the Australian Medical Equipment industry average (13.8x).

PE vs Market: RHT is poor value based on its PE Ratio (94.5x) compared to the Australian market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RHT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RHT is overvalued based on its PB Ratio (4.7x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Resonance Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Resonance Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Resonance Health performed over the past 5 years?

30.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RHT has a large one-off gain of A$136.5K impacting its June 30 2021 financial results.

Growing Profit Margin: RHT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: RHT has become profitable over the past 5 years, growing earnings by 30.2% per year.

Accelerating Growth: RHT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RHT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: RHT's Return on Equity (5%) is considered low.


Financial Health

How is Resonance Health's financial position?


Financial Position Analysis

Short Term Liabilities: RHT's short term assets (A$9.7M) exceed its short term liabilities (A$611.7K).

Long Term Liabilities: RHT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: RHT is debt free.

Reducing Debt: RHT has not had any debt for past 5 years.

Debt Coverage: RHT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: RHT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Resonance Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RHT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RHT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RHT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Mitchell Wells (46 yo)

0.25

Tenure

AU$553,975

Compensation

Mr. Mitchell M. Wells, LLB, B. Comm., served as Company Secretary at Resonance Health Limited since April 2021 until May 31, 2021. He served as Non-Executive Director of Resonance Health Ltd. since Februar...


Leadership Team

Experienced Management: RHT's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: RHT's board of directors are considered experienced (7.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.


Top Shareholders

Company Information

Resonance Health Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Resonance Health Limited
  • Ticker: RHT
  • Exchange: ASX
  • Founded: 1987
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$53.032m
  • Shares outstanding: 461.15m
  • Website: https://www.resonancehealth.com

Location

  • Resonance Health Limited
  • 141 Burswood Road
  • Ground Floor, Suite 2
  • Burswood
  • Western Australia
  • 6100
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:04
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.